e in patients reduces the conversion of cyclophosphamide to the active metabolite, 4-hydroxycyclophosphamide; the effect appears sequence dependent with a greater reduction in the conversion to 4-hydroxycyclophosphamide when thiotepa is administered 1.5 hours prior to the intravenous administration of cyclophosphamide compared to administration of thiotepa after intravenous cyclophosphamide [see clinical pharmacology (12.2) ] . the reduction in 4-hydroxycyclophosphamide levels may potentially reduce efficacy of cyclophosphamide treatment.

product is not labeled with that information.

periodic complete blood counts during the course of treatment with thiotepa. provide supportive care for infections, bleeding, and symptomatic anemia [see adverse reactions (6.1)] . pediatric use information is approved for adienne sa’s tepadina (thiotepa) for injection. however, due to adienne sa’s marketing exclusivity rights, the drug product is not labeled with that information. 5.2 hypersensitivity clinically significant hypersensitivity reactions, including anaphylaxis, have occurred following administration of thiotepa. if anaphylactic or other clinically significant allergic reaction occurs, discontinue treatment with thiotepa, initiate appropriate therapy, and monitor until signs and symptoms resolve [see contraindications (4) , adverse reactions (6.1)] . 5.3 cutaneous toxicity thiotepa and/or its active metabolites may be excreted in part via skin patients receiving high-dose therapy. treatment with thiotepa may cause skin discoloration, pruritus, blistering, desquamation, and peeling that may be more severe in the groin, axillae, skin folds, in the neck area, and under dressings. instruct patients to shower or bathe with water at least twice daily through 48 hours after administration of thiotepa. change occlusive dressing and clean the covered skin at least twice daily through 48 hours after administration of thiotepa. change bed sheets daily during treatment. skin reactions associated with accidental exposure to thiotepa may also occur. wash the skin thoroughly with soap and water in case thiotepa solution contacts the skin. flush mucous membranes in case of thiotepa contact with mucous membranes. 5.4 concomitant use of live and attenuated vaccines do not administer live or attenuated viral or bacterial vaccines to a patient treated with thiotepa until the immunosuppressive effects have resolved. 5.5 hepatic veno-occlusive disease hepatic veno-occlusive disease may occur in patients who have received high-dose thiotepa in conjunction with busulfan and cyclophosphamide. monitor by physical examination, serum transaminases and bilirubin daily through bmt day +28, and provide supportive care to patients who develop hepatic veno-occlusive disease. pediatric use information is approved for adienne sa’s tepadina (thiotepa) for injection. however, due to adienne sa’s marketing exclusivity rights, the drug product is not labeled with that information. 5.6 central nervous system toxicity fatal encephalopathy has occurred in patients treated with high doses of thiotepa. other central nervous system toxicities, such as headache, apathy, psychomotor retardation, disorientation, confusion, amnesia, hallucinations, drowsiness, somnolence, seizures, coma, inappropriate behaviour and forgetfulness have been reported to occur in a dose-dependent manner during or shortly after administration of high-dose thiotepa. do not exceed the recommended dose of thiotepa. if severe or life-threatening central nervous system toxicity occurs, discontinue administration of thiotepa and provide supportive care. pediatric use information is approved for adienne sa’s tepadina (thiotepa) for injection. however, due to adienne sa’s marketing exclusivity rights, the drug product is not labeled with that information. 5.7 carcinogenicity like many alkylating agents, thiotepa has been reported to be carcinogenic when administered to laboratory animals [see nonclinical toxicity (13.1) ] . carcinogenicity is shown most clearly in studies using mice, but there is some evidence of carcinogenicity in man. there is an increased risk of a secondary malignancy with use of thiotepa. 5.8 embryo-fetal toxicity based on the mechanism of action and findings in animals, thiotepa can cause fetal harm when administered to a pregnant woman. there are no adequate and well-controlled studies of thiotepa in pregnant women. thiotepa given by the intraperitoneal (ip) route was teratogenic in mice at doses ≥ 1 mg/kg (3.2 mg/m 2 ), approximately 8-fold less than the maximum recommended human therapeutic dose (0.8 mg/kg, 27 mg/m 2 ), based on body-surface area. thiotepa given by the ip route was teratogenic in rats at doses ≥ 3 mg/kg (21 mg/m 2 ), approximately equal to the maximum recommended human therapeutic dose, based on body-surface area. thiotepa was lethal to rabbit fetuses at a dose of 3 mg/kg (41 mg/m 2 ), approximately two times the maximum recommended human therapeutic dose based on body-surface area. advise pregnant women of the potential risk to the fetus [see use in specific populations (8.1 , 8.3 )] . advise females of reproductive potential to use highly effective contraception during and after treatment with thiotepa for at least 6 months after therapy. advise males of reproductive potential to use effective contraception during and after treatment with thiotepa for at least 1 year after therapy [see use in specific populations (8.1 , 8.3 )] .

re frequently than weekly. malignant effusions the recommended dose of thiotepa for injection for treatment of malignant effusions is 0.6 to 0.8 mg/kg intracavitary. administration is usually effected through the same tubing which is used to remove the fluid from the cavity involved. doses should be given at 1 to 4 week intervals. initially the higher dose in the given range is commonly administered. the maintenance dose should be adjusted weekly on the basis of pretreatment control blood counts and subsequent blood counts. maintenance doses should not be administered more frequently than weekly. superficial papillary carcinoma of the urinary bladder the recommended dose of thiotepa for injection for treatment of superficial papillary carcinoma of the urinary bladder is 60 mg in 30 to 60 ml of sodium chloride injection into the bladder by catheter. the solution should be retained for 2 hours. if the patient finds it impossible to retain 60 ml for 2 hours, the dose may be given in a volume of 30 ml. the patient may be repositioned every 15 minutes for maximum area contact. the usual course of treatment is once a week for 4 weeks. the course may be repeated if necessary, but second and third courses must be given with caution since bone-marrow depression may be increased. pediatric use information is approved for adienne sa 's tepadina (thiotepa) for injection. however, due to adienne sa 's marketing exclusivity rights, the drug product is not labeled with that information. 2.2 preparation instructions thiotepa for injection is a cytotoxic drug. follow applicable special handling and disposal procedures 1 . reconstitution reconstitute thiotepa for injection 15 mg with 1.5 ml of sterile water for injection. using a syringe fitted with a needle, aseptically withdraw 1.5 ml of sterile water for injection. inject the content of the syringe into the vial through the rubber stopper. remove the syringe and needle, and mix manually by repeated inversions. reconstitute thiotepa for injection 100 mg with 10 ml of sterile water for injection. using a syringe fitted with a needle, aseptically withdraw 10 ml of sterile water for injection. inject the content of the syringe into the vial through the rubber stopper. remove the syringe and needle, and mix manually by repeated inversions. the reconstituted solution is hypotonic and must be diluted in saline prior to administration. reconstituted solutions, free of visible particulate matter, may occasionally show opalescence; such solutions can still be used for further dilution. if not used immediately after reconstitution, the product is stable for 8 hours when stored at 2°c to 8°c (36° to 46°f). dilution in the infusion bag prior to administration, dilute the reconstituted solution further with an appropriate volume of sodium chloride 0.9% solution for injection to obtain a final thiotepa for injection concentration between 0.5 and 1 mg/ml. dilute thiotepa for injection as recommended in table 2. table 2: dilution of thiotepa for injection in the infusion bag calculated thiotepa for injection dose dilution volume (sodium chloride 0.9% solution for injection) less than 250 mg appropriate volume to obtain a final concentration of 0.5 to 1 mg/ml 250 mg to 500 mg 500 ml or appropriate volume to obtain a final concentration of 0.5 to 1 mg/ml greater than 500 mg 1000 ml or appropriate volume to obtain a final concentration of 0.5 to 1 mg/ml after dilution the product is stable for 24 hours when stored at 2°c to 8°c (36° to 46°f) and for 4 hours when stored at 25°c (77°f). from a microbiological point of view, the product should be used immediately. inspect the diluted solution visually for particulate matter and discoloration prior to administration. use thiotepa for injection diluted solutions only if free of visible particulate matter. filter using a 0.2 micron filter prior to administration. filtering does not alter solution potency

ls are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. adverse reactions with treatment of adenocarcinoma of the breast, adenocarcinoma of the ovary, malignant effusions and superficial papillary carcinoma of the urinary bladder gastrointestinal : nausea, vomiting, abdominal pain, anorexia. general : fatigue, weakness. febrile reaction and discharge from a subcutaneous lesion may occur as the result of breakdown of tumor tissue. hypersensitivity reactions : allergic reactions - rash, urticaria, laryngeal edema, asthma, anaphylactic shock, wheezing. local reactions : contact dermatitis, pain at the injection site. neurologic : dizziness, headache, blurred vision. renal : dysuria, urinary retention, chemical cystitis or hemorrhagic cystitis. reproductive : amenorrhea, interference with spermatogenesis. respiratory : prolonged apnea has been reported when succinylcholine was administered prior to surgery, following combined use of thiotepa and other anticancer agents. it was theorized that this was caused by decrease of pseudocholinesterase activity caused by the anticancer drugs. skin : dermatitis, alopecia. skin depigmentation has been reported following topical use. special senses : conjunctivitis. pediatric use information is approved for adienne sa’s tepadina (thiotepa) for injection. however, due to adienne sa’s marketing exclusivity rights, the drug product is not labeled with that information. 6.2 postmarketing experience because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. the following adverse reactions have been identified during post approval use of thiotepa in preparative regimens prior to allogeneic or autologous hematopoietic progenitor (stem) cell transplantation (hsct) in adult and pediatric patients. blood and lymphatic system disorders: febrile bone marrow aplasia. cardiac disorders: bradycardia, cardiac failure congestive, cardio-respiratory arrest, pericardial effusion, pericarditis, right ventricular hypertrophy. congenital, familial and genetic disorders: aplasia. ear and labyrinth disorders: deafness. eye disorders: blindness, eyelid ptosis, papilledema, strabismus. gastrointestinal disorders: ascites, dysphagia, enterocolitis, gastritis, palatal disorder. general disorders and administration site conditions: device related infection, gait disturbance, malaise, multi-organ failure, pain. hepatobiliary disorders: hepatomegaly. immune system disorders: bone marrow transplant rejection, immunosuppression. infections and infestations: acute sinusitis, bronchopulmonary aspergillosis, candida sepsis, enterococcal infection, epstein-barr virus infection, escherichia sepsis, fusarium infection, gastroenteritis, infection, lower respiratory tract infection fungal, lower respiratory tract infection viral, parainfluenza virus infection, pneumonia legionella, relapsing fever, respiratory tract infection, sepsis, septic shock, staphylococcal bacteremia, staphylococcal infection, systemic candida, urinary tract infection. injury, poisoning and procedural complications: refractoriness to platelet transfusion, subdural hematoma. investigations: coagulation test abnormal, hemoglobin decreased, klebsiella test positive, nuclear magnetic resonance imaging brain abnormal, transaminases increased, weight increased. metabolism and nutrition disorders: hyponatremia. neoplasms benign, malignant and unspecified (incl. cysts and polyps): breast cancer metastatic, central nervous system lymphoma, leukemia recurrent, lymphoma, malignant neoplasm progression, metastatic neoplasm, post transplant lymphoproliferative disorder. nervous system disorders: aphasia, brain injury, bulbar palsy, central nervous system lesion, cerebral microangiopathy, cerebral ventricle dilatation, cerebrovascular accident, cognitive disorder, convulsion, coordination abnormal, encephalitis, encephalopathy, hemiplegia, hypotonia, leukoencephalopathy, memory impairment, motor dysfunction, neurotoxicity, quadriparesis, speech disorder, tremor, viith nerve paralysis, white matter lesion. psychiatric disorders: delirium, depression, disorientation, suicidal ideation. renal and urinary disorders: renal failure, nephropathy toxic. respiratory, thoracic and mediastinal disorders: acute respiratory distress, aspiration, dyspnea exertional, interstitial lung disease, lung disorder, pneumonitis, pulmonary arteriopathy, pulmonary sepsis, pulmonary veno-occlusive disease, respiratory distress, respiratory failure, pulmonary hypertension. skin and subcutaneous tissue disorders: stevens-johnson syndrome and toxic epidermal necrolysis. vascular disorders: capillary leak syndrome.

e in patients reduces the conversion of cyclophosphamide to the active metabolite, 4-hydroxycyclophosphamide; the effect appears sequence dependent with a greater reduction in the conversion to 4-hydroxycyclophosphamide when thiotepa is administered 1.5 hours prior to the intravenous administration of cyclophosphamide compared to administration of thiotepa after intravenous cyclophosphamide [see clinical pharmacology (12.2) ] . the reduction in 4-hydroxycyclophosphamide levels may potentially reduce efficacy of cyclophosphamide treatment.

nd malformations of the skeletal system of the fetus) at doses approximately 0.125 and 1 times, respectively, the maximum recommended human daily dose on a mg/m 2 basis. thiotepa was lethal to rabbit fetuses at approximately 2 times the maximum recommended human therapeutic dose based on body-surface area [see data] . consider the benefits and risks of thiotepa for the mother and possible risks to the fetus when prescribing thiotepa to a pregnant woman. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. data animal data thiotepa given by the ip route in mice at doses ≥ 1 mg/kg (3.2 mg/m 2 ), approximately 8-fold less than the maximum recommended human therapeutic dose based on body-surface area, and in rats at doses ≥ 3 mg/kg (21 mg/m 2 ), approximately equal to the maximum recommended human therapeutic dose based on body-surface area, resulted in various malformations including neural tube defects, omphalocele, renal agenesis, atresia ani, limb and digit defects, cleft palate, micrognathia, other skeletal anomalies in the skull, vertebrae and ribs, and reduced skeletal ossification. thiotepa was lethal to rabbit fetuses at a dose of 3 mg/kg (41 mg/m 2 ), approximately 2 times the maximum recommended human therapeutic dose based on body-surface area. 8.2 lactation risk summary there is no information regarding the presence of thiotepa in human milk, the effects on the breastfed infant, or the effects on milk production. because of the potential for serious adverse reactions, including the potential for tumorigenicity shown for thiotepa in animal studies, advise patients not to breastfeed during thiotepa treatment. 8.3 females and males of reproductive potential pregnancy testing thiotepa can cause fetal harm when administered to a pregnant female. verify the pregnancy status of females of reproductive potential prior to initiating thiotepa therapy. contraception females advise females of reproductive potential to avoid pregnancy during thiotepa treatment and for at least 6 months after the final dose of thiotepa. advise females to immediately report pregnancy [see use in specific populations (8.1) ] . males thiotepa may damage spermatozoa and testicular tissue, resulting in possible genetic abnormalities. males with female sexual partners of reproductive potential should use effective contraception during thiotepa treatment and for at least 1 year after the final dose of thiotepa [see nonclinical toxicology (13.1) ] . infertility based on nonclinical findings, male and female fertility may be compromised by treatment with thiotepa. inform male patients about the possibility of sperm conservation before the start of therapy [see nonclinical toxicology (13.1) ] . 8.4 pediatric use safety and effectiveness of thiotepa in neonates have not been established. safety and effectiveness of thiotepa for treatment of adenocarcinoma of the breast, adenocarcinoma of the ovary, malignant effusions and superficial papillary carcinoma of the urinary bladder in pediatric patients have not been established. pediatric use information is approved for adienne sa’s tepadina (thiotepa) for injection. however, due to adienne sa’s marketing exclusivity rights, the drug product is not labeled with that information. 8.5 geriatric use clinical studies of thiotepa for treatment of adenocarcinoma of the breast, adenocarcinoma of the ovary, malignant effusions and superficial papillary carcinoma of the urinary bladder did not include sufficient numbers of subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreasing hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. 8.6 renal impairment in patients with moderate (creatinine clearance (clcr) of 30 ml/min to 59 ml/min) renal impairment, decreased renal excretion may result in increased plasma levels of thiotepa and tepa [see clinical pharmacology (12.2) ] . this may result in increased toxicity. monitor patients with moderate to severe (clcr <30 ml/min) renal impairment for signs and symptoms of toxicity following treatment with thiotepa for an extended period of time. 8.7 hepatic impairment thiotepa is extensively metabolized in the liver. patients with moderate (bilirubin levels greater than 1.5 times to 3 times the upper limit of normal and any ast) hepatic impairment may have increased plasma levels of thiotepa [see clinical pharmacology (12.2) ] . this may result in toxicity. monitor patients with moderate to severe (bilirubin levels greater than 3 times upper limit of normal and any ast) hepatic impairment for signs and symptoms of toxicity following treatment with thiotepa for an extended period of time.

major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. data animal data thiotepa given by the ip route in mice at doses ≥ 1 mg/kg (3.2 mg/m 2 ), approximately 8-fold less than the maximum recommended human therapeutic dose based on body-surface area, and in rats at doses ≥ 3 mg/kg (21 mg/m 2 ), approximately equal to the maximum recommended human therapeutic dose based on body-surface area, resulted in various malformations including neural tube defects, omphalocele, renal agenesis, atresia ani, limb and digit defects, cleft palate, micrognathia, other skeletal anomalies in the skull, vertebrae and ribs, and reduced skeletal ossification. thiotepa was lethal to rabbit fetuses at a dose of 3 mg/kg (41 mg/m 2 ), approximately 2 times the maximum recommended human therapeutic dose based on body-surface area.

thiotepa between 20 mg to 250 mg/m 2 as an intravenous bolus or infusion up to 4 hours, the mean thiotepa clearance ranged from 14.6 l/hr/m 2 (23%) to 27.9 l/hr/m 2 (69%). in adult population, the mean terminal elimination half-life ranged from 1.4 hours (7%) to 3.7 hours (14%) for thiotepa and from 4.9 hours to 17.6 hours (20%) for tepa. metabolism thiotepa undergoes hepatic metabolism. in vitro data suggests that cyp3a4 and cyp2b6 may be responsible for the metabolism of thiotepa to tepa, a major active metabolite. ex cretion in adult patients, urinary excretion of thiotepa accounted for less than 2% of the dose and tepa accounted for 11% or less of the dose. spec i fic populations hepatic impairment the exposure (as measured by area under the curve (auc)) of thiotepa increased by 1.6-fold and 1.8-fold following administration of multiple thiotepa doses of 7 mg/kg administered every 2 days with cyclophosphamide in two adult patients who had liver metastases with moderate hepatic impairment compared to the exposure observed in one patient with normal hepatic function. the effect of severe hepatic impairment on thiotepa exposure is unknown. renal impairment the exposure (as measured by auc) of thiotepa increased by 1.4-fold and tepa increased by 2.6-fold following administration of multiple doses of 120 mg/m 2 /day in one patient with moderate renal impairment (clcr = 38 ml/min) administered cyclophosphamide plus thiotepa plus carboplatin, compared to exposure of thiotepa in patients with normal renal function. the effects of severe renal impairment or end-stage renal disease on thiotepa exposure are unknown. drug interactions the clinical relevance of in vitro inhibition of the cytochrome p450 enzymes described below is unknown, but it cannot be excluded that the systemic exposure of thiotepa or medicinal products that are substrates for these enzymes may be affected with concomitant administration with thiotepa. effect of cytochrome p450 modulators on thiotepa in vitro data demonstrates that cyp3a4 and cyp2b6 inhibitors decrease the metabolism of thiotepa [see drug interactions (7.1) ] . effect of thiotepa on cytochrome p450 2b6 in vitro data demonstrates that thiotepa inhibits cyp2b6. effect of thiotepa on cyclophosphamide the administration of thiotepa 1.5 hours prior to intravenous cyclophosphamide in patients administered cyclophosphamide plus thiotepa plus carboplatin decreased the auc of 4-hydroxycyclophosphamide by 26% and maximal concentrations of 4-­hydroxycyclophosphamide by 62%, compared to administration of cyclophosphamide prior to thiotepa. pediatric use information is approved for adienne sa’s tepadina (thiotepa) for injection. however, due to adienne sa’s marketing exclusivity rights, the drug product is not labeled with that information.

pa given intravenously (iv) to rats (1 mg/kg once per week for 52 weeks) produced an increased incidence of malignant tumors (abdominal cavity sarcoma, lymphosarcoma myelosis, seminoma, fibrosarcoma, salivary gland hemangioendothelioma, mammary sarcoma, pheochromocytoma) and benign tumors. the lowest reported carcinogenic dose in mice (1.15 mg/kg, 3.68 mg/m 2 ) is approximately 7-fold less than the maximum recommended human therapeutic dose based on body-surface area. the lowest reported carcinogenic dose in rats (0.7 mg/kg, 4.9 mg/m 2 ) is approximately 6-fold less than the maximum recommended human therapeutic dose based on body-surface area. thiotepa was mutagenic in in vitro assays in salmonella typhimurium , e coli , chinese hamster lung and human lymphocytes. chromosomal aberrations and sister chromatid exchanges were observed in vitro with thiotepa in bean root tips, human lymphocytes, chinese hamster lung, and monkey lymphocytes. mutations were observed with oral thiotepa in mouse at doses >2.5 mg/kg (8 mg/m 2 ). the mouse micronucleus test was positive with intraperitoneal administration of >1 mg/kg (3.2 mg/m 2 ). other positive in vivo chromosomal aberration or mutation assays included drosophila melanogaster , chinese hamster marrow, murine marrow, monkey lymphocyte, and murine germ cell. thiotepa impaired fertility in male mice at oral or intraperitoneal doses ≥0.7 mg/kg (2.24 mg/m 2 ), approximately 12-fold less than the maximum recommended human therapeutic dose based on body-surface area. thiotepa (0.5 mg) inhibited implantation in female rats when instilled into the uterine cavity. thiotepa interfered with spermatogenesis in mice at ip doses ≥0.5 mg/kg (1.6 mg/m 2 ), approximately 17-fold less than the maximum recommended human therapeutic dose based on body-surface area. thiotepa interfered with spermatogenesis in hamsters at an ip dose of 1 mg/kg (4.1 mg/m 2 ), approximately 7-fold less than the maximum recommended human therapeutic dose based on body-surface area.

) to rats (1 mg/kg once per week for 52 weeks) produced an increased incidence of malignant tumors (abdominal cavity sarcoma, lymphosarcoma myelosis, seminoma, fibrosarcoma, salivary gland hemangioendothelioma, mammary sarcoma, pheochromocytoma) and benign tumors. the lowest reported carcinogenic dose in mice (1.15 mg/kg, 3.68 mg/m 2 ) is approximately 7-fold less than the maximum recommended human therapeutic dose based on body-surface area. the lowest reported carcinogenic dose in rats (0.7 mg/kg, 4.9 mg/m 2 ) is approximately 6-fold less than the maximum recommended human therapeutic dose based on body-surface area. thiotepa was mutagenic in in vitro assays in salmonella typhimurium , e coli , chinese hamster lung and human lymphocytes. chromosomal aberrations and sister chromatid exchanges were observed in vitro with thiotepa in bean root tips, human lymphocytes, chinese hamster lung, and monkey lymphocytes. mutations were observed with oral thiotepa in mouse at doses >2.5 mg/kg (8 mg/m 2 ). the mouse micronucleus test was positive with intraperitoneal administration of >1 mg/kg (3.2 mg/m 2 ). other positive in vivo chromosomal aberration or mutation assays included drosophila melanogaster , chinese hamster marrow, murine marrow, monkey lymphocyte, and murine germ cell. thiotepa impaired fertility in male mice at oral or intraperitoneal doses ≥0.7 mg/kg (2.24 mg/m 2 ), approximately 12-fold less than the maximum recommended human therapeutic dose based on body-surface area. thiotepa (0.5 mg) inhibited implantation in female rats when instilled into the uterine cavity. thiotepa interfered with spermatogenesis in mice at ip doses ≥0.5 mg/kg (1.6 mg/m 2 ), approximately 17-fold less than the maximum recommended human therapeutic dose based on body-surface area. thiotepa interfered with spermatogenesis in hamsters at an ip dose of 1 mg/kg (4.1 mg/m 2 ), approximately 7-fold less than the maximum recommended human therapeutic dose based on body-surface area.

] . advise females to report pregnancy immediately [see warnings and precautions (5.8) ] . advise patients that thiotepa can produce infertility. inform male patients about the possibility of sperm conservation before the start of therapy [see use in specific populations (8.3) ] . lactation advise patients to avoid breastfeeding while receiving thiotepa [see use in specific populations (8.2) ] . secondary malignancies inform patients that thiotepa can increase the risk of secondary malignancy [see warnings and precautions (5.7) ] . manufactured by: msn laboratories private limited telangana – 509 228, india distributed by: msn pharmaceuticals inc. piscataway, nj 08854 -3714 issued on: 09/2019